Literature DB >> 21839301

Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosis.

Pia Moinzadeh1, Nicolas Hunzelmann2, Thomas Krieg2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21839301     DOI： 10.1016/j.jaad.2011.04.029

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  6 in total

Review 1.  [Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems].

Authors:  M Frerix; F M P Meier; W Hermann; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

Review 2.  Management of Raynaud's phenomenon and digital ischemia.

Authors:  Ariane L Herrick
Journal:  Curr Rheumatol Rep       Date:  2013-01       Impact factor: 4.592

3.  Is There Any Relationship between the Chronicity of Chronic Anal Fissure and Endothelin-1?

Authors:  Won-Kyung Kang
Journal:  J Korean Soc Coloproctol       Date:  2011-10-31

4.  Raynaud's phenomenon.

Authors:  Ashraful Haque; Michael Hughes
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

5.  Sildenafil in the treatment of pressure ulcer: a randomised clinical trial.

Authors:  Shadi Farsaei; Hossein Khalili; Effat S Farboud; Zahra Khazaeipour
Journal:  Int Wound J       Date:  2013-06-04       Impact factor: 3.315

6.  Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis.

Authors:  S Bellando-Randone; G Lepri; C Bruni; J Blagojevic; A Radicati; L Cometi; A De Paulis; M Matucci-Cerinic; S Guiducci
Journal:  Clin Rheumatol       Date:  2015-12-03       Impact factor: 2.980
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.